{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:10Z","timestamp":1785521470918,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Over expression of 9-\n                      <jats:italic>O-<\/jats:italic>\n                      acetylated sialoglycoproteins (Neu5,9Ac\n                      <jats:sub>2<\/jats:sub>\n                      -GPs, abbreviated as\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP) has been demonstrated as a disease-associated antigen on the lymphoblasts of childhood acute lymphoblastic leukaemia (ALL). Achatinin-H, a lectin, has selective affinity towards terminal 9-\n                      <jats:italic>O-<\/jats:italic>\n                      acetylated sialic acids-\u03b12-6-\n                      <jats:italic>N<\/jats:italic>\n                      acetylated galactosamine. Exploring this affinity, enhanced expression of\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP was observed, at the onset of disease, followed by its decrease with chemotherapy and reappearance with relapse. In spite of treatment, patients retain the diseased cells referred to as minimal residual disease (MRD) responsible for relapse. Our aim was to select a suitable template by using the differential expression of\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP along with other known CD antigens to monitor MRD in peripheral blood (PB) and bone marrow (BM) of Indian patients with B- or T-ALL during treatment and correlate it with the disease status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A two-year longitudinal follow-up study was done with 109 patients from the onset of the disease till the end of chemotherapy, treated under MCP841protocol. Paired samples of PB (n = 1667) and BM (n = 999) were monitored by flow cytometry. Three templates selected for this investigation were\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP\n                      <jats:sup>+<\/jats:sup>\n                      CD10\n                      <jats:sup>+<\/jats:sup>\n                      CD19\n                      <jats:sup>+<\/jats:sup>\n                      or\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP\n                      <jats:sup>+<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD19\n                      <jats:sup>+<\/jats:sup>\n                      for B-ALL and\n                      <jats:italic>O<\/jats:italic>\n                      AcSGP\n                      <jats:sup>+<\/jats:sup>\n                      CD7\n                      <jats:sup>+<\/jats:sup>\n                      CD3\n                      <jats:sup>+<\/jats:sup>\n                      for T-ALL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using each template the level of MRD detection reached 0.01% for a patient in clinical remission (CR). 81.65% of the patients were in CR during these two years while the remaining relapsed. Failure in early clearance of lymphoblasts, as indicated by higher MRD, implied an elevated risk of relapse. Soaring MRD during the chemotherapeutic regimen predicted clinical relapse, at least a month before medical manifestation. Irrespective of B- or T-lineage ALL, the MRD in PB and BM correlated well.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A range of MRD values can be predicted for the patients in CR, irrespective of their lineage, being 0.03 \u00b1 0.01% (PB) and 0.05 \u00b1 0.015% (BM). These patients may not be stated as normal with respect to the presence of MRD. Hence, MRD study beyond two-years follow-up is necessary to investigate further reduction in MRD, thereby ensuring their disease-free survival. Therefore, we suggest use of these templates for MRD detection, during and post-chemotherapy for proper patient management strategies, thereby helping in personalizing the treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2407-8-40","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T14:13:37Z","timestamp":1201875217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["RETRACTED ARTICLE: Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study"],"prefix":"10.1186","volume":"8","author":[{"given":"Suchandra","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmila","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,1]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(01)00516-2","volume":"2","author":"CH Pui","year":"2001","unstructured":"Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukaemia \u2013 current status and future perspectives. Lancet Oncol. 2001, 2: 597-607. 10.1016\/S1470-2045(01)00516-2.","journal-title":"Lancet Oncol"},{"key":"978_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ejca.2004.11.004","volume":"41","author":"I Magrath","year":"2005","unstructured":"Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutierrez M, Liewehr D, Pai S, Sagar TG, Venzon D: Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period. Eur J Cancer. 2005, 41: 1570-83. 10.1016\/j.ejca.2004.11.004. Review.","journal-title":"Eur J Cancer"},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1365-2141.2000.02105.x","volume":"110","author":"C Mandal","year":"2000","unstructured":"Mandal C, Chatterjee M, Sinha D: Investigation of 9-O-acetylated sialoglycoconjugates in childhood acute lymphoblastic leukemia. Br J Haematol. 2000, 110: 801-12. 10.1046\/j.1365-2141.2000.02105.x.","journal-title":"Br J Haematol"},{"key":"978_CR4","doi-asserted-by":"publisher","first-page":"1R","DOI":"10.1093\/glycob\/cwj008","volume":"16","author":"A Varki","year":"2006","unstructured":"Varki A, Angata T: Siglecs \u2013 the major subfamily of I-type lectins. Glycobiology. 2006, 16: 1R-27R. 10.1093\/glycob\/cwj008.","journal-title":"Glycobiology"},{"key":"978_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.zool.2003.10.002","volume":"107","author":"R Schauer","year":"2004","unstructured":"Schauer R: Sialic acids: fascinating sugars in higher animals and man. Zoology (Jena). 2004, 107: 49-64.","journal-title":"Zoology (Jena)"},{"key":"978_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF01954221","volume":"46","author":"C Mandal","year":"1990","unstructured":"Mandal C, Mandal C: Sialic acid binding lectins. Experientia. 1990, 46: 433-41. 10.1007\/BF01954221.","journal-title":"Experientia"},{"key":"978_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.coph.2005.03.003","volume":"5","author":"PR Crocker","year":"2005","unstructured":"Crocker PR: Siglecs in innate immunity. Curr Opin Pharmacol. 2005, 5: 431-7. 10.1016\/j.coph.2005.03.003.","journal-title":"Curr Opin Pharmacol"},{"key":"978_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.6206564","volume":"225","author":"DA Cheresh","year":"1984","unstructured":"Cheresh DA, Reisfeld RA, Varki AP: O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science. 1984, 225: 844-6. 10.1126\/science.6206564.","journal-title":"Science"},{"key":"978_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0165-2478(97)00116-8","volume":"59","author":"M Vater","year":"1997","unstructured":"Vater M, Kniep B, Gross HJ, Claus C, Dippold W, Schwartz-Albiez R: The 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B lymphocytes. Immunol Lett. 1997, 59: 151-7. 10.1016\/S0165-2478(97)00116-8.","journal-title":"Immunol Lett"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1086\/425519","volume":"190","author":"S Ghosh","year":"2004","unstructured":"Ghosh S, Bandyopadhyay S, Mukherjee K, Mallick A, Pal S, Mandal C, Bhattacharya DK, Mandal C: Antibodies directed against O-acetylated sialoglycoconjugates accelerate complement activation in Leishmania donovani promastigotes. J Infect Dis. 2004, 190: 2010-9. 10.1086\/425519.","journal-title":"J Infect Dis"},{"key":"978_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1086\/382752","volume":"189","author":"AK Chava","year":"2004","unstructured":"Chava AK, Chatterjee M, Sharma V, Sundar S, Mandal C: Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-O-acetylated sialoglycans. J Infect Dis. 2004, 189: 1257-1264. 10.1086\/382752.","journal-title":"J Infect Dis"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0008-6215(94)00311-3","volume":"268","author":"G Sen","year":"1995","unstructured":"Sen G, Mandal C: The specificity of the binding site of Achatinin-H, a sialic-acid binding lectin from Achatina fulica. Carbohydr Res. 1995, 268: 115-25. 10.1016\/0008-6215(94)00311-3.","journal-title":"Carbohydr Res"},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/bj2540195","volume":"254","author":"S Basu","year":"1988","unstructured":"Basu S, Mandal C, Allen AK: Chemical modification studies of a unique sialic acid binding lectin from the snail Achatina fulica. Biochem J. 1988, 254: 195-202.","journal-title":"Biochem J"},{"key":"978_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/bj2570065","volume":"257","author":"C Mandal","year":"1989","unstructured":"Mandal C, Basu S, Mandal C: Physicochemical studies on Achatinin-H, a novel sialic acid binding lectin. Biochem J. 1989, 257: 65-71.","journal-title":"Biochem J"},{"key":"978_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/sj\/leu\/2401239","volume":"13","author":"D Sinha","year":"1999","unstructured":"Sinha D, Mandal C, Bhattacharya DK: Identification of 9-O-acetyl sialoglycoconjugates (9-O-AcSGs) as biomarkers in childhood acute lymphoblastic leukemia using a lectin, Achatinin-H, as a probe. Leukaemia. 1999, 13: 119-25. 10.1038\/sj\/leu\/2401239.","journal-title":"Leukaemia"},{"key":"978_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj\/leu\/2401312","volume":"13","author":"D Sinha","year":"1999","unstructured":"Sinha D, Mandal C, Bhattacharya DK: A novel method for prognostic evaluation of childhood acute lymphoblastic leukemia. Leukaemia. 1999, 13: 309-12. 10.1038\/sj\/leu\/2401312.","journal-title":"Leukaemia"},{"key":"978_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0145-2126(98)00184-2","volume":"23","author":"D Sinha","year":"1999","unstructured":"Sinha D, Mandal C, Bhattacharya DK: Development of a simple, blood based lymphoproliferation assay to assess the clinical status of patients with acute lymphoblastic leukaemia. Leukaemia Res. 1999, 23: 433-9. 10.1016\/S0145-2126(98)00184-2.","journal-title":"Leukaemia Res"},{"key":"978_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0145-2126(99)00093-4","volume":"23","author":"D Sinha","year":"1999","unstructured":"Sinha D, Mandal C, Bhattacharya DK: A colorimetric assay to evaluate the chemotherapeutic response of children with acute lymphoblastic leukaemia (ALL) employing Achatinin-H: a 9-O-acetyl sialic acid binding lectin. Leukaemia Res. 1999, 23: 803-9. 10.1016\/S0145-2126(99)00093-4.","journal-title":"Leukaemia Res"},{"key":"978_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ijc.20246","volume":"111","author":"S Pal","year":"2004","unstructured":"Pal S, Ghosh S, Bandyopadhyay S, Mandal C, Bandhyopadhyay S, Kumar Bhattacharya D, Mandal C: Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia. Int J Cancer. 2004, 111: 270-7. 10.1002\/ijc.20246.","journal-title":"Int J Cancer"},{"key":"978_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/glycob\/cwh111","volume":"14","author":"S Pal","year":"2004","unstructured":"Pal S, Ghosh S, Mandal C, Kohla G, Brossmer R, Isecke R, Merling A, Schauer R, Schwartz-Albiez R, Bhattacharya DK, Mandal C: Purification and characterization of 9-O-acetylated sialoglycoproteins from leukemic cells and their potential as immunological tool for monitoring childhood acute lymphoblastic leukemia. Glycobiology. 2004, 14: 859-70. 10.1093\/glycob\/cwh111.","journal-title":"Glycobiology"},{"key":"978_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1023\/A:1019692329568","volume":"18","author":"S Pal","year":"2001","unstructured":"Pal S, Chatterjee M, Bhattacharya DK, Bandhyopadhyay S, Mandal C, Mandal C: O-Acetyl sialic acid specific IgM in childhood acute lymphoblastic leukemia. Glycoconjugate J. 2001, 18: 529-37. 10.1023\/A:1019692329568.","journal-title":"Glycoconjugate J"},{"key":"978_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/glycob\/10.6.539","volume":"10","author":"S Pal","year":"2000","unstructured":"Pal S, Chatterjee M, Bhattacharya DK, Bandhyopadhyay S, Mandal C: Identification and purification of cytolytic antibodies directed against O-acetylated sialic acid in childhood acute lymphoblastic leukemia. Glycobiology. 2000, 10: 539-49. 10.1093\/glycob\/10.6.539.","journal-title":"Glycobiology"},{"key":"978_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.clinbiochem.2004.01.001","volume":"37","author":"S Pal","year":"2004","unstructured":"Pal S, Bandyopadhyay S, Chatterjee M, Bhattacharya DK, Minto L, Hall AG, Mandal C: Antibodies against 9-O-acetylated sialoglycans: a potent marker to monitor clinical status in childhood acute lymphoblastic leukemia. Clinical Biochemistry. 2004, 37: 395-403. 10.1016\/j.clinbiochem.2004.01.001.","journal-title":"Clinical Biochemistry"},{"key":"978_CR24","first-page":"7","volume":"43","author":"S Bandyopadhyay","year":"2006","unstructured":"Bandyopadhyay S, Chatterjee M, Banavali SD, Pal S, Nair CN, Advani S, Mandal C: Antibodies against 9-O-acetylated sialic acid in childhood acute lymphoblastic leukaemia: A two-year study with 186 samples following protocol MCP943. Ind J Biochem Biophys. 2006, 43: 7-14.","journal-title":"Ind J Biochem Biophys"},{"key":"978_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jim.2004.11.014","volume":"297","author":"S Bandyopadhyay","year":"2005","unstructured":"Bandyopadhyay S, Mukherjee K, Chatterjee M, Bhattacharya DK, Mandal C: Detection of immune-complexed 9-O-acetylated sialoglycoconjugates in the sera of patients with pediatric acute lymphoblastic leukemia. J Immunol Methods. 2005, 297: 13-26. 10.1016\/j.jim.2004.11.014.","journal-title":"J Immunol Methods"},{"key":"978_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jcb.20382","volume":"95","author":"S Ghosh","year":"2005","unstructured":"Ghosh S, Bandyopadhyay S, Mallick A, Pal S, Vlasak R, Bhattacharya DK, Mandal C: Interferon gamma promotes survival of lymphoblasts over expressing 9-O-acetylated sialoglycoconjugates in childhood acute lymphoblastic leukaemia (ALL). J Cell Biochem. 2005, 95: 206-16. 10.1002\/jcb.20382.","journal-title":"J Cell Biochem"},{"key":"978_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2141.2004.05256.x","volume":"128","author":"S Ghosh","year":"2005","unstructured":"Ghosh S, Bandyopadhyay S, Pal S, Das B, Bhattacharya DK, Mandal C: Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia. Br J Haematol. 2005, 128: 35-41. 10.1111\/j.1365-2141.2004.05256.x.","journal-title":"Br J Haematol"},{"key":"978_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/intimm\/dxh198","volume":"17","author":"S Bandyopadhyay","year":"2005","unstructured":"Bandyopadhyay S, Bhattacharyya A, Mallick A, Sen AK, Tripathi G, Das T, Sa G, Bhattacharya DK, Mandal C: Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia. Int Immunol. 2005, 17: 177-91. 10.1093\/intimm\/dxh198.","journal-title":"Int Immunol"},{"key":"978_CR29","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998, 352: 1731-8. 10.1016\/S0140-6736(98)04058-6.","journal-title":"Lancet"},{"key":"978_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood-2006-01-0322","volume":"108","author":"C Flotho","year":"2001","unstructured":"Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D: Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood. 2001, 108: 1050-7. 10.1182\/blood-2006-01-0322.","journal-title":"Blood"},{"key":"978_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1008366814109","volume":"10","author":"S Advani","year":"1999","unstructured":"Advani S, Pai S, Venzon D, Adde M, Kurkure PK, Nair CN, Sirohi B, Banavali SD, Hawaldar R, Kolhatkar BB, Vats T, Magrath I: Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann Oncol. 1999, 10: 167-76. 10.1023\/A:1008366814109.","journal-title":"Ann Oncol"},{"key":"978_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/beha.2002.0182","volume":"15","author":"D Campana","year":"2002","unstructured":"Campana D, Coustan-Smith E: Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002, 15: 1-19. 10.1053\/beha.2002.0182.","journal-title":"Best Pract Res Clin Haematol"},{"key":"978_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.V72.1.299.299","volume":"72","author":"CA Hurwitz","year":"1988","unstructured":"Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI: Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988, 72: 299-307.","journal-title":"Blood"},{"key":"978_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/sj\/leu\/2401279","volume":"13","author":"P Lucio","year":"1999","unstructured":"Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF: Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999, 13: 419-27. 10.1038\/sj\/leu\/2401279.","journal-title":"Leukemia"},{"key":"978_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1365-2141.2003.04393.x","volume":"121","author":"D Campana","year":"2003","unstructured":"Campana D: Determination of minimal residual disease in leukemia patients. Br J Haematol. 2003, 121: 823-38. 10.1046\/j.1365-2141.2003.04393.x.","journal-title":"Br J Haematol"},{"key":"978_CR36","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","volume":"100","author":"E Coustan-Smith","year":"2002","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002, 100: 2399-402. 10.1182\/blood-2002-04-1130.","journal-title":"Blood"},{"key":"978_CR37","first-page":"769","volume":"47","author":"J Kode","year":"2006","unstructured":"Kode J, Dudhal N, Banvali S, Chiplunkar S: T-cell receptor gamma and delta junctional gene rearrangements as diagnostic and prognostic biomarker for T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2006, 47: 769-70.","journal-title":"Leuk Lymphoma"},{"key":"978_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pbc.20309","volume":"45","author":"SJ Corey","year":"2005","unstructured":"Corey SJ: Targeted Therapy: For Kids, Too. Pediatr Blood Cancer. 2005, 45: 623-634. 10.1002\/pbc.20309.","journal-title":"Pediatr Blood Cancer"}],"updated-by":[{"DOI":"10.1186\/s12885-026-16553-7","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:02:46Z","timestamp":1785517366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1471-2407-8-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,12]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-40","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]},"assertion":[{"value":"23 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-026-16553-7","URL":"https:\/\/doi.org\/10.1186\/s12885-026-16553-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"40"}}